{
  "schemaVersion": 2,
  "eyebrow": "Endocrinology",
  "title": "Diabetes Mellitus Screening",
  "summary": "Screen adults and selected youth for dysglycemia using validated plasma glucose or A1C testing, confirm abnormal results when hyperglycemia is not unequivocal, and recognize settings—including HIV and pediatric risk—in which test selection and interpretation require modification.",
  "seoDescription": "Physician guide to diabetes screening: who to test, diagnostic assays and thresholds, confirmation of abnormal results, youth screening, and HIV-specific considerations.",
  "clinicalQuestion": "Who should be screened for diabetes, which test should be ordered, and how should abnormal results be confirmed?",
  "specialty": "Endocrinology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "diabetes screening",
    "prediabetes screening",
    "type 2 diabetes",
    "fasting plasma glucose",
    "A1C",
    "oral glucose tolerance test",
    "HIV diabetes screening",
    "pediatric diabetes screening"
  ],
  "keyTakeaways": [
    "ADA-supported screening begins at age 35 years for asymptomatic adults; A1C, fasting plasma glucose, and 2-hour 75-g OGTT are accepted screening tests.[8]",
    "Diabetes is diagnosed by A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL, or 2-hour plasma glucose at least 200 mg/dL during a 75-g OGTT; an abnormal result should be repeated when hyperglycemia is not unequivocal.[10]",
    "In people with HIV receiving ART, use plasma glucose rather than A1C to diagnose diabetes because A1C may underestimate dysglycemia; obtain random or fasting glucose at entry to care and annually thereafter.[10]",
    "Screen asymptomatic youth at risk for type 2 diabetes or prediabetes; ADA and AAP endorse screening in this population.[11]"
  ],
  "sections": [
    {
      "id": "who-to-screen",
      "eyebrow": "Eligibility",
      "heading": "Who should be screened",
      "intro": "Screening applies to asymptomatic people; diagnostic testing is indicated when symptoms or marked hyperglycemia are present.",
      "paragraphs": [
        "The ADA proposes healthcare-setting screening for all asymptomatic adults aged 35 years or older.[8] Available search evidence does not provide a complete risk-factor-based earlier-screening algorithm, pregnancy screening protocol, rescreening interval, or stopping rule; consult current ADA Standards for those decisions.",
        "ADA and AAP recommend screening asymptomatic youth for type 2 diabetes and prediabetes.[11] The supplied evidence does not specify the pediatric eligibility criteria or testing interval; use current pediatric guidance to determine which children and adolescents meet risk-based screening criteria."
      ],
      "bullets": [],
      "subsections": [],
      "table": {
        "caption": "Screening populations supported by supplied guidance.[8][11]",
        "columns": [
          "Population",
          "Screening approach supported by supplied evidence",
          "Important limitation"
        ],
        "rows": [
          [
            "Asymptomatic adults aged 35 years or older",
            "Screen in a healthcare setting with A1C, fasting plasma glucose, or 2-hour 75-g OGTT.[8]",
            "The supplied results do not specify repeat interval or earlier adult risk-based criteria."
          ],
          [
            "Asymptomatic youth at risk for type 2 diabetes or prediabetes",
            "ADA and AAP recommend screening.[11]",
            "Risk criteria, preferred test, and interval are not detailed in the supplied result."
          ]
        ]
      }
    },
    {
      "id": "tests-and-thresholds",
      "eyebrow": "Test selection",
      "heading": "Choose a validated glycemic test",
      "intro": "Use venous plasma glucose or laboratory A1C; each assay detects a different glycemic phenotype.",
      "paragraphs": [
        "Diabetes may be diagnosed by elevated venous plasma glucose or elevated hemoglobin A1C.[7] The accepted diagnostic thresholds cited in the supplied guidance are fasting plasma glucose at least 126 mg/dL (7.0 mmol/L), 2-hour plasma glucose at least 200 mg/dL (11.1 mmol/L) after a standard 75-g OGTT, or A1C at least 6.5%.[10]",
        "A1C, fasting plasma glucose, and 2-hour OGTT are all proposed screening options for asymptomatic adults.[8] Test selection should be driven by clinical practicality and the likelihood of misleading A1C interpretation. A1C alone identifies only a minority of diabetes cases identified collectively by A1C and glucose-based criteria, underscoring that discordance between assays is clinically meaningful rather than exceptional.[22]"
      ],
      "bullets": [
        "Order fasting plasma glucose when a fasting specimen is feasible and a plasma glucose-based diagnosis is desired.[10]",
        "Use a 2-hour 75-g OGTT when postchallenge dysglycemia is a concern or when clarification is needed after discordant screening results; diabetes is diagnosed at a 2-hour value of at least 200 mg/dL.[10]",
        "Use A1C only when its interpretation is reliable for the individual patient; the diagnostic threshold is at least 6.5%.[10]"
      ],
      "subsections": [],
      "table": {
        "caption": "Diagnostic thresholds for diabetes mellitus.[10]",
        "columns": [
          "Test",
          "Diabetes threshold",
          "Operational note"
        ],
        "rows": [
          [
            "Fasting plasma glucose",
            "At least 126 mg/dL (7.0 mmol/L).[10]",
            "Use venous plasma glucose criteria."
          ],
          [
            "2-hour plasma glucose after 75-g OGTT",
            "At least 200 mg/dL (11.1 mmol/L).[10]",
            "Requires a standard 75-g glucose load."
          ],
          [
            "A1C",
            "At least 6.5%.[10]",
            "May be misleading in people with HIV receiving ART.[10]"
          ]
        ]
      }
    },
    {
      "id": "confirmation-and-discordance",
      "eyebrow": "Interpretation",
      "heading": "Confirm abnormal screening results and resolve discordance",
      "intro": "Repeat testing is essential unless the clinical presentation establishes diabetes unequivocally.",
      "paragraphs": [
        "When A1C and fasting glucose are discordant in people with HIV, the cited ADA approach is to repeat the abnormal test and diagnose diabetes only if the repeat result remains above the diagnostic cutoff.[10] This confirmation principle is particularly important when screening detects isolated, modest abnormalities rather than unequivocal hyperglycemia.",
        "A random glucose greater than 200 mg/dL in people with HIV should trigger further evaluation with fasting blood glucose.[10] The supplied sources do not provide a general-population random-glucose diagnostic pathway or symptom-based exception to confirmation; follow current ADA diagnostic guidance for those scenarios."
      ],
      "bullets": [
        "Do not assume a normal A1C excludes diabetes when glucose results are abnormal or when a condition may distort A1C interpretation.[10][22]",
        "Repeat an abnormal result rather than averaging discordant values; the diagnosis requires persistence of an abnormal result in the setting described above.[10]",
        "For an abnormal random glucose in a person with HIV, obtain fasting plasma glucose rather than relying on A1C for diagnosis.[10]"
      ],
      "subsections": [],
      "table": {
        "caption": "Practical response to common screening-result patterns.[10][22]",
        "columns": [
          "Result pattern",
          "Next action",
          "Rationale"
        ],
        "rows": [
          [
            "A1C and fasting glucose are discordant in a person with HIV",
            "Repeat the abnormal test; diagnose diabetes only if repeat testing remains above its diagnostic cutoff.[10]",
            "A1C may underestimate dysglycemia in people with HIV receiving ART.[10]"
          ],
          [
            "Random glucose above 200 mg/dL in a person with HIV",
            "Obtain fasting blood glucose.[10]",
            "Plasma glucose criteria are preferred for diagnosis after ART initiation.[10]"
          ],
          [
            "Normal A1C but abnormal glucose-based test",
            "Do not dismiss the glucose abnormality; pursue glucose-based confirmation as appropriate.[10][22]",
            "A1C alone has limited sensitivity relative to combined A1C and glucose-based case ascertainment.[22]"
          ]
        ]
      }
    },
    {
      "id": "hiv-specific-screening",
      "eyebrow": "Special population",
      "heading": "Screening in people with HIV",
      "intro": "ART and HIV-related factors can make A1C an unreliable diagnostic test.",
      "paragraphs": [
        "Among people with HIV, A1C is highly specific but insensitive for diabetes diagnosis and can underestimate diabetes risk.[10] The HIVMA/IDSA guidance reports that ADA standards recommend against using A1C to diagnose diabetes in people with HIV receiving ART; after ART initiation, use plasma glucose criteria for diagnosis.[10]",
        "Obtain random or fasting glucose and A1C before starting ART. At entry to HIV care and annually thereafter, obtain either random or fasting glucose; if random glucose is abnormal, obtain fasting glucose.[10] A1C may still be followed in patients with established diabetes, but correlate it with measured glucose because ART may cause over- or underestimation on an individual basis.[10]"
      ],
      "bullets": [
        "At HIV entry to care: obtain random or fasting glucose and A1C before ART.[10]",
        "After ART initiation: use plasma glucose criteria for diabetes diagnosis.[10]",
        "For established diabetes: monitor A1C at least every 6 months, with an A1C goal below 7% cited by HIVMA/IDSA in accordance with ADA guidance, while individualizing interpretation against glucose values.[10]"
      ],
      "subsections": [],
      "table": {
        "caption": "HIV-specific approach to diabetes screening and diagnosis.[10]",
        "columns": [
          "Clinical moment",
          "Recommended measurement",
          "Interpretive action"
        ],
        "rows": [
          [
            "Before ART",
            "Random or fasting glucose plus A1C.[10]",
            "Establish baseline; recognize that A1C may not reliably represent glycemia."
          ],
          [
            "Entry to care and annually thereafter",
            "Random or fasting glucose.[10]",
            "If random glucose is abnormal, obtain fasting glucose.[10]"
          ],
          [
            "After ART initiation",
            "Plasma glucose criteria for diagnosis.[10]",
            "Avoid diagnosing diabetes solely from A1C.[10]"
          ],
          [
            "Established diabetes",
            "A1C at least every 6 months.[10]",
            "Assess concordance with glucose before applying an individual A1C target.[10]"
          ]
        ]
      }
    },
    {
      "id": "type-1-diabetes-screening",
      "eyebrow": "Emerging practice",
      "heading": "Presymptomatic type 1 diabetes screening remains selective",
      "intro": "Islet autoantibody screening is not yet routine population practice.",
      "paragraphs": [
        "The principal goal of type 1 diabetes screening programs in youth is to reduce diabetic ketoacidosis at diagnosis and support research participation.[17] However, type 1 diabetes screening is still conducted primarily in research-based settings, and real-world testing remains inconsistent.[19]",
        "An analysis from the ASK study suggests that autoantibody screening may be cost-effective in areas with high diabetic ketoacidosis rates, but the supplied evidence does not establish a universal U.S. population-screening recommendation, testing panel, or surveillance schedule.[9]"
      ],
      "bullets": [
        "Consider referral to an established type 1 diabetes screening or research program when family history, patient preference, or local program availability makes autoantibody testing actionable.[17][19]",
        "Do not substitute presymptomatic type 1 diabetes autoantibody testing for standard glucose-based screening for type 2 diabetes or dysglycemia.[8][19]"
      ],
      "subsections": [],
      "table": {
        "caption": "",
        "columns": [],
        "rows": []
      }
    }
  ],
  "faq": [
    {
      "question": "Which tests can be used to screen asymptomatic adults for diabetes?",
      "answer": "A1C, fasting plasma glucose, and 2-hour plasma glucose after a 75-g OGTT are accepted screening tests for asymptomatic adults.[8] Diabetes thresholds are A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL, and 2-hour OGTT glucose at least 200 mg/dL.[10]"
    },
    {
      "question": "Should a single abnormal screening test establish diabetes?",
      "answer": "When results are not unequivocal, repeat the abnormal assay for confirmation. In people with HIV with A1C-glucose discordance, diabetes should be diagnosed only when repeat testing remains above the diagnostic cutoff.[10]"
    },
    {
      "question": "Is A1C appropriate for diabetes diagnosis in people with HIV?",
      "answer": "Not as the preferred diagnostic test after ART initiation. HIVMA/IDSA cites A1C insensitivity and recommends plasma glucose criteria; obtain random or fasting glucose at entry to care and annually, with fasting glucose after an abnormal random result.[10]"
    },
    {
      "question": "Should asymptomatic youth be screened for diabetes?",
      "answer": "Yes, ADA and AAP recommend screening asymptomatic youth for type 2 diabetes and prediabetes, although the supplied result does not provide detailed risk criteria or intervals.[11]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "- IIER - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 2,
      "title": "Garzulys - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761497s000lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 3,
      "title": "Diagnosis and Screening of Pediatric Diabetes Mellitus",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/diagnosis-and-screening-of-pediatric-diabetes-mellitus",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 4,
      "title": "Diagnostic Methods for Diabetes and Glucose Metabolism",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/diagnostic-methods-for-diabetes-and-glucose-metabolism",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 5,
      "title": "Treatment of Diabetes in Older Adults: An Endocrine ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article/104/5/1520/5413486",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 6,
      "title": "Physician Process and Patient Outcome Measures... : Medical Care",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/lww-medicalcare/fulltext/2004/09000/physician_process_and_patient_outcome_measures_for.3.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 7,
      "title": "Executive Summary: Guidelines and Recommendations for ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/clinchem/article/69/8/777/7226243",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 8,
      "title": "Guidelines and Recommendations for Laboratory Analysis ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/clinchem/article/69/8/808/7226244",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 9,
      "title": "Establishing Screening Programs for Presymptomatic Type 1 ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article/110/8/2371/8103687",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 10,
      "title": "Primary Care Guidance for Persons With HIV",
      "detail": "www.idsociety.org",
      "url": "https://www.idsociety.org/practice-guideline/primary-care-management-of-people-with-hiv",
      "authors": "www.idsociety.org",
      "host": "www.idsociety.org"
    },
    {
      "number": 11,
      "title": "Screening and Diagnosis of Prediabetes and Diabetes in ...",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatrics/article/146/3/e20200265/36758/Screening-and-Diagnosis-of-Prediabetes-and",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 12,
      "title": "U.S. Selected Practice Recommendations for ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.15585%2Fmmwr.rr7303a1&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 13,
      "title": "Diabetes Mellitus",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/books/chapter-pdf/795344/aap_9781581106244-part02-diabetes_mellitus.pdf",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 14,
      "title": "10. Cardiovascular Disease and Risk Management",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S010&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 15,
      "title": "11. Chronic Kidney Disease and Risk Management",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S011&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 16,
      "title": "2. Diagnosis and Classification of Diabetes: Standards of Care ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2FDC25-S002&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 17,
      "title": "Screening Programs for Type 1 Diabetes in Youth",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatrics/article/157/6/e2025075728/207530/Screening-Programs-for-Type-1-Diabetes-in-Youth",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 18,
      "title": "Prioritizing Health | Diabetes, Diet and GLP-1 RAs",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2025/06/01/01/prioritizing-health-diabetes-diet-and-glp-1-ras",
      "authors": "www.acc.org",
      "host": "www.acc.org"
    },
    {
      "number": 19,
      "title": "Type 1 Diabetes Screening in Pediatrics",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 20,
      "title": "Guidelines and Clinical Policy",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/guidelines",
      "authors": "www.acc.org",
      "host": "www.acc.org"
    },
    {
      "number": 21,
      "title": "Follow-up Report on the Diagnosis of Diabetes Mellitus",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/26/11/3160/22281/Follow-up-Report-on-the-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 22,
      "title": "2. Classification and Diagnosis of Diabetes: Standards of ...",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/43/Supplement_1/S14/30640/2-Classification-and-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 23,
      "title": "Diagnosis and Classification of Diabetes Mellitus",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/37/Supplement_1/S81/37753/Diagnosis-and-Classification-of-Diabetes-Mellitus",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    },
    {
      "number": 24,
      "title": "Tests for Screening and Diagnosis of Type 2 Diabetes",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/clinical/article/27/4/132/1673/Tests-for-Screening-and-Diagnosis-of-Type-2",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "- IIER - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "1\"\"morecrfcr 1 brg,rlm,~andi\"\"\"'1 atakrgaspirilbrh«rtattack or'1roks, berall>3n'l'\"'n sOOium mayd>:r...,thO benelitof~Mn H 1>1\"\"\"\"a.1 --NlND•\"\"'~'llliin,in\"\"\"'terokofh«rtatt1ck.heartfalure. 1 nd atakrgt, bb>:ltinnirgdn,:iNrfarin ■ ta<irg\"1J ntherdn,:i \"1rOOl lh>le ran llafili!I. ThaMilcis hi;II« ITi",
      "score": 0.15676242
    },
    {
      "number": 2,
      "title": "Garzulys - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761497s000lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness (5.3). Medication Errors: Accidental mix-ups between insu",
      "score": 0.31393534
    },
    {
      "number": 3,
      "title": "Diagnosis and Screening of Pediatric Diabetes Mellitus",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/diagnosis-and-screening-of-pediatric-diabetes-mellitus",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Clinical evaluation integrates measurements of fasting plasma glucose, random plasma glucose, glycated haemoglobin and oral glucose tolerance testing.",
      "score": 0.42935818
    },
    {
      "number": 4,
      "title": "Diagnostic Methods for Diabetes and Glucose Metabolism",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/diagnostic-methods-for-diabetes-and-glucose-metabolism",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Diagnosis of diabetes and assessment of glucose metabolism rely on a combination of biochemical assays and dynamic tests that capture both fasting and post.",
      "score": 0.19479668
    },
    {
      "number": 5,
      "title": "Treatment of Diabetes in Older Adults: An Endocrine ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article/104/5/1520/5413486",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by D LeRoith · 2019 · Cited by 756 — Screening, treatment, and management of diabetes mellitus and complications in older patients. in this guideline covers all aspects of the",
      "score": 0.3901278
    },
    {
      "number": 6,
      "title": "Physician Process and Patient Outcome Measures... : Medical Care",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/lww-medicalcare/fulltext/2004/09000/physician_process_and_patient_outcome_measures_for.3.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Analyses indicated that provider adherence to diabetes guidelines (ie, hemoglobin A 1c, foot, eye, renal, and lipid screens) and patient outcome measures (ie, glycemic, lipid, and hypertension control plus nonsmoking status) are comparable or better in VAMCs than reported elsewhere. VAMCs with highe",
      "score": 0.3643935
    },
    {
      "number": 7,
      "title": "Executive Summary: Guidelines and Recommendations for ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/clinchem/article/69/8/777/7226243",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by DB Sacks · 2023 · Cited by 39 — Diabetes can be diagnosed by demonstrating increased concentrations of glucose in venous plasma or increased hemoglobin A1c (Hb A1c) in the",
      "score": 0.22281043
    },
    {
      "number": 8,
      "title": "Guidelines and Recommendations for Laboratory Analysis ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/clinchem/article/69/8/808/7226244",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by DB Sacks · 2023 · Cited by 683 — The ADA proposes that all asymptomatic people 35 years of age or more should be screened in a healthcare setting. Hb A1c, FPG or 2-h OGTT are",
      "score": 0.156221
    },
    {
      "number": 9,
      "title": "Establishing Screening Programs for Presymptomatic Type 1 ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/jcem/article/110/8/2371/8103687",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by SB Leichter · 2025 · Cited by 26 — An analysis of data from the ASK study found that AAb screening could be cost-effective if conducted in an area with high rates of DKA and with screening",
      "score": 0.09522337
    },
    {
      "number": 10,
      "title": "Primary Care Guidance for Persons With HIV",
      "detail": "www.idsociety.org",
      "url": "https://www.idsociety.org/practice-guideline/primary-care-management-of-people-with-hiv",
      "authors": "www.idsociety.org",
      "host": "www.idsociety.org",
      "snippet": "Random or fasting serum glucose and HbA1c should be obtained prior to starting ART. If random blood glucose is abnormal, fasting blood glucose should be obtained. After initiation of ART, only plasma glucose criteria should be used to diagnose diabetes. A random glucose >200 mg/dL should prompt furt",
      "score": 0.40825373
    },
    {
      "number": 11,
      "title": "Screening and Diagnosis of Prediabetes and Diabetes in ...",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatrics/article/146/3/e20200265/36758/Screening-and-Diagnosis-of-Prediabetes-and",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "The American Diabetes Association and American Academy of Pediatrics recommend screening for type 2 diabetes and prediabetes in asymptomatic youth. It is",
      "score": 0.24050733
    },
    {
      "number": 12,
      "title": "U.S. Selected Practice Recommendations for ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.15585%2Fmmwr.rr7303a1&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "by KM Curtis · 2024 · Cited by 209 — Other screening: Patients with hypertension, diabetes, or thrombophilia can use (U.S. MEC 1) or generally can use (U.S. MEC 2) IUDs (1).",
      "score": 0.20875941
    },
    {
      "number": 13,
      "title": "Diabetes Mellitus",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/books/chapter-pdf/795344/aap_9781581106244-part02-diabetes_mellitus.pdf",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "Blood glucose monitoring 4 or more times per day is recommended to help identify blood glucose patterns and to adjust insulin and/or food intake.",
      "score": 0.19947985
    },
    {
      "number": 14,
      "title": "10. Cardiovascular Disease and Risk Management",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S010&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA's current clinical practice recommendations and is",
      "score": 0.18295078
    },
    {
      "number": 15,
      "title": "11. Chronic Kidney Disease and Risk Management",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S011&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA's current clinical practice recommendations and is",
      "score": 0.17393301
    },
    {
      "number": 16,
      "title": "2. Diagnosis and Classification of Diabetes: Standards of Care ...",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2FDC25-S002&link_type=DOI",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and",
      "score": 0.14924625
    },
    {
      "number": 17,
      "title": "Screening Programs for Type 1 Diabetes in Youth",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatrics/article/157/6/e2025075728/207530/Screening-Programs-for-Type-1-Diabetes-in-Youth",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "The main aim of the T1D screening program is to reduce rates of diabetic ketoacidosis (DKA) at diagnosis and to participate in research",
      "score": 0.11900848
    },
    {
      "number": 18,
      "title": "Prioritizing Health | Diabetes, Diet and GLP-1 RAs",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/latest-in-cardiology/articles/2025/06/01/01/prioritizing-health-diabetes-diet-and-glp-1-ras",
      "authors": "www.acc.org",
      "host": "www.acc.org",
      "snippet": "Key Points For Patients\n\nWhen discussing weight and lifestyle change, it is important to take a patient-centered approach. This includes taking care to minimize weight stigma, which can damage the patient-clinician relationship, result in delayed or canceled care and lower treatment efficacy.14,15 I",
      "score": 0.11073072
    },
    {
      "number": 19,
      "title": "Type 1 Diabetes Screening in Pediatrics",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "Unfortunately, T1D screening is still done primarily in research-based settings, while real-world testing practices remain inconsistent.",
      "score": 0.11055777
    },
    {
      "number": 20,
      "title": "Guidelines and Clinical Policy",
      "detail": "www.acc.org",
      "url": "https://www.acc.org/guidelines",
      "authors": "www.acc.org",
      "host": "www.acc.org",
      "snippet": "# \n\n# Guidelines & Clinical Policy\n\nTransforming CV Care For All\n\n## Newest Guideline\n\nCardiovascular-Kidney-Metabolic Syndrome\n\n## Mobile Guideline Clinical App\n\nGuidelines always within reach.\n\nFor more than 75 years, the ACC has been a trusted source of evidence-based cardiovascular guidance, del",
      "score": 0.0872602
    },
    {
      "number": 21,
      "title": "Follow-up Report on the Diagnosis of Diabetes Mellitus",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/26/11/3160/22281/Follow-up-Report-on-the-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "Thus, “normal” would now be defined as a FPG <100 mg/dl. The revised thresholds are shown in Table 1. In addition, the Committee concludes that",
      "score": 0.6271529
    },
    {
      "number": 22,
      "title": "2. Classification and Diagnosis of Diabetes: Standards of ...",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/43/Supplement_1/S14/30640/2-Classification-and-Diagnosis-of-Diabetes",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "The A1C test, with a diagnostic threshold of ≥6.5% (48 mmol/mol), diagnoses only 30% of the diabetes cases identified collectively using A1C,",
      "score": 0.55391616
    },
    {
      "number": 23,
      "title": "Diagnosis and Classification of Diabetes Mellitus",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/care/article/37/Supplement_1/S81/37753/Diagnosis-and-Classification-of-Diabetes-Mellitus",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "The group did note that those with A1C levels above the laboratory “normal” range but below the diagnostic cut point for diabetes (6.0 to <6.5%)",
      "score": 0.38359568
    },
    {
      "number": 24,
      "title": "Tests for Screening and Diagnosis of Type 2 Diabetes",
      "detail": "diabetesjournals.org",
      "url": "https://diabetesjournals.org/clinical/article/27/4/132/1673/Tests-for-Screening-and-Diagnosis-of-Type-2",
      "authors": "diabetesjournals.org",
      "host": "diabetesjournals.org",
      "snippet": "Proposed tests for diabetes screening are numerous and vary from history- and anthropometric-based questionnaires to proteomics-based risk",
      "score": 0.32575697
    }
  ],
  "publishedAt": "2026-08-20T23:53:33.109001Z",
  "updatedAt": "2026-08-20T23:53:33.109001Z",
  "readingMinutes": 4,
  "slug": "diabetes-mellitus-screening"
}